Search results for "Atrial fibrillation"
Benefits of thyroid screening unclear, Task Force says
Researchers for the U.S. Preventive Services Task Force (USPSTF) suggested in a review that more research is needed to determine the benefits of screening asymptomatic individuals for thyroid dysfunction.
https://immattersacp.org/weekly/archives/2014/10/28/2.htm
28 Oct 2014
Boxed warning for metoclopramide, alert for zonisamide
A summary of approvals, recalls, warnings and alerts.
https://immattersacp.org/archives/2009/04/fda.htm
1 Apr 2009
Chronic fatigue syndrome gets new criteria
This issue covers topics including chronic fatigue, dietary cholesterol, and conference coverage about managing afib and giving medical lectures.
https://immattersacp.org/archives/2015/06/editors.htm
1 Jun 2015
Correction to a previous issue
An item in last week's ACP InternistWeekly required correction.
https://immattersacp.org/weekly/archives/2014/03/11/9.htm
11 Mar 2014
New analyses differ on whether dabigatran raises MI risk
Two analyses published in the past week compared rates of myocardial infarction (MI) in patients taking dabigatran or warfarin and came to differing results.
https://immattersacp.org/weekly/archives/2012/01/10/1.htm
10 Jan 2012
A can't-miss cause of resistant hypertension
More than 20% of patients with resistant hypertension have primary aldosteronism, an underrecognized cause of hypertension and cardiovascular disease.
https://immattersacp.org/archives/2021/05/a-cant-miss-cause-of-resistant-hypertension.htm
1 May 2021
Managing the elderly with cardiovascular disease
As patients are living longer, they're seeking more care for their cardiovascular diseases, as well as the accompanying comorbities such as diabetes. Effective therapy works in the older population, say the experts.
https://immattersacp.org/archives/2011/10/CVD.htm
1 Oct 2011
Expanded approval on rivaroxaban, reassurance on dabigatran
This regulatory update covers an expanded indication for rivaroxaban and an announcement that bleeding rates do not appear to be higher with dabigatran than with warfarin.
https://immattersacp.org/archives/2013/01/fda.htm
1 Jan 2013
Comparison with warfarin comes out well for dabigatran
Dabigatran (Pradaxa) was associated with a lower risk of clot-related strokes, intracranial hemorrhage, and death than warfarin, according to a recent study conducted by the FDA.
https://immattersacp.org/weekly/archives/2014/05/20/8.htm
20 May 2014
New drugs approved for acute coronary syndromes, HIV
Recalls, warnings, and approvals.
https://immattersacp.org/archives/2011/10/fda.htm
1 Oct 2011